[go: up one dir, main page]

PE106300A1 - Imidazoquinoxalinas como inhibidores de la proteina tirosina cinasa - Google Patents

Imidazoquinoxalinas como inhibidores de la proteina tirosina cinasa

Info

Publication number
PE106300A1
PE106300A1 PE1998000776A PE00077698A PE106300A1 PE 106300 A1 PE106300 A1 PE 106300A1 PE 1998000776 A PE1998000776 A PE 1998000776A PE 00077698 A PE00077698 A PE 00077698A PE 106300 A1 PE106300 A1 PE 106300A1
Authority
PE
Peru
Prior art keywords
alkynyl
alkyl
compound
imidazoquinoxalins
inhibitors
Prior art date
Application number
PE1998000776A
Other languages
English (en)
Inventor
Jagabandhu Das
Edwin J Iwanowicz
Derek J Norris
Joel C Barrish
Jacques Y Roberge
Gary L Schieven
Ping Chen
Ramesh Padmanabha
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE106300A1 publication Critical patent/PE106300A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UNA IMIDAZOQUINOXALINA DE FORMULA I DONDE p ES 0-4; R1, R2 Y R3 SON H, R6, OH, OR6, SH, SR6, C(O)qH, -OC(O)qR6, SO3H, HALO, CIANO, ENTRE OTROS; q ES 1 o 2; R6 ES ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; R4 Y R5 SON H, R6 o -C(O)R6 o JUNTO CON N FORMAN UN ANILLO DE 3-8 MIEMBROS, OPCIONALMENTE SUSTITUIDO POR Z1, Z2 Y Z3; R7, R8, R9, R10, R11 Y R12 SON H, R6, O R7 Y R8 O R9, R10 Y R11 SON ALQUILENO O ALQUENILENO FORMANDO PARTE DE UN ANILLO DE 3-8 MIEMBROS; R13, R14 Y R15 SON ALQUILO O FENILO; Z1, Z2, Z3 SON H, Z6, OH, OZ6, SH, SZ6, C(O)qH, -OC(O)qZ6, ENTRE OTROS; Z6 ES ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, ENTRE OTROS. UN COMPUESTO PREFERIDO ES N-(2-CLORO-6-METILFENIL)-8-NITROIMIDAZO[1,5-a]-QUINOXALIN-4-AMINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. TAMBIEN JUNTO AL COMPUESTO I SE UTILIZA UN ANTIINFLAMATORIO, ANTIPROLIFERATIVO, INMUNOSUPRESOR. EL COMPUESTO I PUEDE SER UTIL PARA TRATAR UN PADECIMIENTO O DESORDEN ASOCIADO CON LA PROTEINA TIROSINA CINASA COMO RECHAZO DE TRANSPLANTE, ARTRITIS REUMATOIDE, ESCLEROSIS MULTIPLE, LUPUS, INJERTO, HIPERSENSIBILIDAD MEDIADA POR LAS CELULAS T, PSORIASIS, TIROIDITIS DE HASHIMOTO, SINDROME DE GUILLEN-BARRE, DERMATITIS, ASMA, CANCER
PE1998000776A 1997-08-25 1998-08-25 Imidazoquinoxalinas como inhibidores de la proteina tirosina cinasa PE106300A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5677097P 1997-08-25 1997-08-25
US6915997P 1997-12-09 1997-12-09

Publications (1)

Publication Number Publication Date
PE106300A1 true PE106300A1 (es) 2000-01-23

Family

ID=26735691

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000776A PE106300A1 (es) 1997-08-25 1998-08-25 Imidazoquinoxalinas como inhibidores de la proteina tirosina cinasa

Country Status (5)

Country Link
US (1) US6235740B1 (es)
AR (1) AR013441A1 (es)
AU (1) AU8681798A (es)
PE (1) PE106300A1 (es)
WO (1) WO1999009845A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1066286B1 (en) * 1998-03-04 2009-04-29 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
US20060258686A1 (en) * 1998-05-29 2006-11-16 Cheresh David A Method of treatment of myocardial infarction
US20030130209A1 (en) * 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
US20040214836A1 (en) * 1998-05-29 2004-10-28 Cheresh David A. Method of treatment of myocardial infarction
AU6605200A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
EP1194152A4 (en) 1999-06-30 2002-11-06 Merck & Co Inc Links to SRC kinase inhibition
WO2001000213A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
US20030176454A1 (en) * 2000-05-15 2003-09-18 Akira Yamada N-coating heterocyclic compounds
CA2424303A1 (en) * 2000-10-03 2002-04-11 Bristol-Myers Squibb Company Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
US6869956B2 (en) * 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
HUP0304045A3 (en) * 2001-02-01 2005-05-30 Bristol Myers Squibb Company P Use of ikb-kinase inhibitors for treating of inflammatory and immune diseases and pharmaceutical compositions containing them
GB0127922D0 (en) * 2001-11-21 2002-01-16 Novartis Ag Organic compounds
AU2002359489B2 (en) * 2001-11-27 2008-10-30 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of EGF-R and Her2 kinases
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
US20040180898A1 (en) * 2003-03-03 2004-09-16 Bang-Chi Chen Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines
US7880017B2 (en) * 2003-11-11 2011-02-01 Allergan, Inc. Process for the synthesis of imidazoles
US7183305B2 (en) * 2003-11-11 2007-02-27 Allergan, Inc. Process for the synthesis of imidazoles
US20060025419A1 (en) * 2004-06-25 2006-02-02 Ann Richmond Imidazoquinoxaline compound for the treatment of melanoma
US8003657B2 (en) * 2004-10-13 2011-08-23 Merck Patent Gmbh Heterocyclic substituted bisarylurea derivatives
CA2646316C (en) 2006-03-15 2016-05-24 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
ES2376492T3 (es) * 2006-03-23 2012-03-14 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores.
JP2010504362A (ja) * 2006-09-25 2010-02-12 アレテ セラピューティクス， インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
CN101616919B (zh) * 2006-12-28 2012-10-10 雅培制药有限公司 聚（adp核糖）聚合酶抑制剂
WO2008130619A2 (en) * 2007-04-20 2008-10-30 Trustees Of Boston College A composition comprising an inhibitor of pde4 and/or pde7
WO2009068320A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
CN101918408A (zh) * 2007-11-30 2010-12-15 惠氏有限责任公司 作为磷酸二酯酶10的抑制剂的芳基和杂芳基稠合的咪唑并[1,5-a]吡嗪
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
US20100075973A1 (en) * 2008-08-28 2010-03-25 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
KR20110132559A (ko) 2009-03-05 2011-12-08 아스텔라스세이야쿠 가부시키가이샤 퀴녹살린 화합물
US8361962B2 (en) * 2009-07-27 2013-01-29 Roche Palo Alto Llc Tricyclic inhibitors of JAK
MX2012002641A (es) * 2009-09-10 2012-03-14 Hoffmann La Roche Inhibidores de cinasa janus (jak).
RU2012116003A (ru) * 2009-09-21 2013-10-27 Ф.Хоффманн-Ля Рош Аг Макроциклические ингибиторы jak
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
WO2012033101A1 (ja) 2010-09-07 2012-03-15 アステラス製薬株式会社 キノキサリン化合物
US9540379B2 (en) * 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
CA2943687C (en) 2014-03-26 2024-02-13 Astex Therapeutics Ltd Combinations of an fgfr inhibitor and an igf1r inhibitor
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
ES2811845T3 (es) 2015-09-23 2021-03-15 Janssen Pharmaceutica Nv Heterociclos tricíclicos para el tratamiento del cáncer
US11542247B2 (en) 2015-09-23 2023-01-03 Janssen Pharmaceutica Nv Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer
WO2022166548A1 (zh) * 2021-02-03 2022-08-11 苏州欧康维视生物科技有限公司 吡唑取代的咪唑并[1,2-a]喹喔啉衍生物的盐型及晶型
CA3257212A1 (en) * 2022-08-03 2025-03-19 Abbisko Therapeutics Co., Ltd. Fused three-cycle PRMT5 inhibitor containing nitrogen, its preparation process and its pharmaceutical use
AU2024222203A1 (en) * 2023-02-17 2025-10-02 Nanjing Synnocare Pharmaceutical Technology Co., Ltd. Mir-124 inducer, and preparation method therefor and use thereof
CN116751198A (zh) * 2023-05-15 2023-09-15 上海工程技术大学 含异硫脲片段的咪唑并六元氮杂化合物的制备方法
WO2025077857A1 (zh) * 2023-10-13 2025-04-17 上海湃隆生物科技有限公司 Prmt5抑制剂在治疗肿瘤或癌症中的用途
US12012414B1 (en) 2024-01-04 2024-06-18 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors
US12187726B1 (en) 2024-02-06 2025-01-07 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrazines as CK2 inhibitors
WO2025180350A1 (zh) * 2024-02-26 2025-09-04 上海湃隆生物科技有限公司 化合物盐的晶型及其制备方法和用途
WO2025180349A1 (zh) * 2024-02-26 2025-09-04 上海湃隆生物科技有限公司 化合物的固体及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197403A (en) 1977-01-07 1980-04-08 Westwood Pharmaceuticals Inc. 4-Aminosubstituted imidazo(1,2-A)quinoxalines
US4191766A (en) 1977-01-07 1980-03-04 Westwood Pharmaceuticals, Inc. Method for reducing immunological response
US4236015A (en) 1977-01-07 1980-11-25 Westwood Pharmaceuticals, Inc. 1-(2-Acylaminophenyl)imidazoles
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
US4229452A (en) 1977-01-07 1980-10-21 Westwood Pharmaceuticals, Inc. Treatment of inflammatory disorders with 4-trifluoromethylimidazo[1,2-a]quinoxaline
US4225724A (en) 1977-01-07 1980-09-30 Westwood Pharmaceuticals, Inc. 1-(2-Phenylureylene)imidazoles
US4160097A (en) 1977-01-07 1979-07-03 Westwind Pharmaceuticals, Inc. 1-(2-Phenylureylene)imidazoles
US4191767A (en) 1977-01-07 1980-03-04 Westwood Pharmaceuticals, Inc. Method for treating fungal infection in mammals with imidazo [1,2-a]quinoxalines
US4198508A (en) 1977-01-07 1980-04-15 Westwood Pharmaceuticals Inc. Process for preparing 4-substituted imidazo[1,2-a]quinoxalines
US4172947A (en) 1977-01-07 1979-10-30 Westwood Pharmaceuticals, Inc. 1-(2-Acylaminophenyl)imidazoles
JPS5632549A (en) 1979-08-27 1981-04-02 Toyo Ink Mfg Co Ltd Pigment composition
US4440929A (en) 1981-07-16 1984-04-03 Usv Pharmaceutical Corporation Imidazoquinoxaline compounds
DK161148C (da) 1988-06-14 1991-11-18 Novo Nordisk As Imidazoquinoxalinforbindelser, fremgangsmaade til fremstilling deraf samt farmaceutiske praeprater indeholdende forbindelserne
DK151890D0 (da) * 1990-06-22 1990-06-22 Ferrosan As Heterocykliske forbindelser deres fremstilling og brug
US5276028A (en) 1990-06-22 1994-01-04 Nordisk A/S Imidazoquinoxaline compounds
DE19506742A1 (de) 1995-02-27 1996-08-29 Bayer Ag Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen
IT1276167B1 (it) 1995-11-24 1997-10-27 Foscama Biomed Chim Farma Imidazo(1,2-alfa)chinossalin-4-ammine attivi come antagonisti adenosinici,procedimento per la loro preparazione e loro composizioni

Also Published As

Publication number Publication date
WO1999009845A1 (en) 1999-03-04
AR013441A1 (es) 2000-12-27
AU8681798A (en) 1999-03-16
US6235740B1 (en) 2001-05-22

Similar Documents

Publication Publication Date Title
PE106300A1 (es) Imidazoquinoxalinas como inhibidores de la proteina tirosina cinasa
PE129799A1 (es) Inhibidores de benzotiazol de la proteina tirosina cinasa
AU6691094A (en) Heteroatom substituted alkyl benzylaminoquinuclidines as substance p antagonists
AU584663B2 (en) Thieno-triazolo-1,4-diazepino-2-carboxylic acid amides
MX9302214A (es) Derivados de taxol y proceso para su preparacion
ZA947970B (en) Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
MX9304646A (es) Nuevas 7-(sustituido)-8-(sustituido)d-9-[(glicilo sustituido)amido]-6-desmetil-6-desoxitetraciclinasy metodo para su produccion.
UA49847C2 (uk) ПОХІДНІ ІМІДАЗОЛУ, ЩО МАЮТЬ СПОРІДНЕНІСТЬ ДО АКТИВНОСТІ <font face="Symbol">a</font>2-РЕЦЕПТОРІВ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЛІКУВАННЯ
NO932872D0 (no) Nye 7-(substituerte)-8-(substituerte)-9-(substituert amino)-6-demetyl-6-deoksy-tetracykliner
MX9304647A (es) 7-(sustituido)-9-[(glicilo sustituido)amido]-6-desmetil-6-desoxitetraciclinas y metodo para su produccion.
BR9906905A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para a preparação de um composto, para tratamento e/ou prevenção de ansiedade e para o tratamento e/ou prevenção de convulsões.
IL156967A0 (en) Camptothecin derivatives
GR3026008T3 (en) Ampa antagonists and a method of treatment therewith
NZ330244A (en) Isoxazole derivatives useful in the treatment of inflammatory diseases
AU554959B2 (en) Triazolo(4,3-a) quinazolin-5-ones
EA200100141A1 (ru) Терапевтическая композиция на основе изофлавоноидов для применения в лечении опухолей цитотоксическими агентами
CA2026775A1 (en) Halo substituted aminotetralins
PT93126A (pt) Processo para a preparacao de eteres carboxialquilicos da 2-amino-7- -hidroxitetralina
ATE174327T1 (de) Bicyclo (2.2.2) oktan-derivate mit cholecystokinin und/oder gastrin antagonistischer wirkung
AR021094A1 (es) Compuestos heterociclicos inhibidores de la fosfodiesterasa iv y su uso para el tratamiento de enfermedades inflamatorias
NZ333229A (es)
ATE216233T1 (de) Indolditerpen alkaloide
SE8304545D0 (sv) Benzamide derivatives
PL295728A1 (en) Method of obtaining novel hydrazones
ES2130923A1 (es) Nuevos derivados gem-difluoro de la fenilacetamida y del acido fenilacetico y sus usos farmaceuticos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal